Apotex Health Corp

APTX · TO · Healthcare / Drug Manufacturers - Specialty & Generic

39.44CAD+0.98 (+2.55%)

Price History

Full chart

Market Stats

Previous Close38.46

Open38.50

Day Range38.50 – 40.10

52-Week Range26.01 – 40.11

Volume504.08K

Market Cap7.12B

P/E (TTM)0.00

Forward P/E16.10

EPS-0.12

Dividend Yield0.19%

50-Day Avg34.32

200-Day Avg33.97

About

Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a broad portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. It operates through three business lines including conventional generic pharmaceuticals; specialty generic pharmaceuticals; and brands & biosimilars. The company has a a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. Apotex Health Corp. was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Jeff Watson
Employees6.00K
Headquarters150 Signet Drive, Toronto, ON, Canada, M9L 1T9, Canada
Websitehttps://www.apotex.com

Leadership

Mr. Jeff WatsonPresident, CEO & Director · b. 1964
Mr. Brian McClellandChief Financial Officer · b. 1968
Mr. Ariel AlonChief Operating Officer · b. 1971
Mr. Francesco TallaricoChief Legal Officer & Global Head of Government Relations · b. 1983
Mr. Barry FishmanChief Corporate Development Officer · b. 1957
Ms. Carina Vassilieva C.C.P., G.R.P., M.B.A.Chief Human Resources Officer · b. 1969
Dr. Kiran Krishnan Ph.D.Senior Vice President of Global Regulatory Affairs · b. 1978
Mr. Martin AresPresident of Canada & Rest of World · b. 1967
Ms. Christine BaederPresident of Apotex USA & LATAM · b. 1973
Dr. Pradeep SanghviExecutive Vice President of Global Research & Development · b. 1965

Financials

Income Statement

Currency: CAD	2024-03-31	2025-03-31	2026-03-31
Total Revenue	2.94B	3.35B	3.49B
Growth (%)	-	+13.92%	+4.21%
Cost of Revenue	1.84B	1.56B	1.55B
Gross Profit	1.10B	1.79B	1.94B
Gross Margin	37.52%	53.55%	55.62%
Operating Expense	1.11B	1.24B	1.16B
Operating Income	-4.66M	552.47M	786.22M
Operating Margin	-0.16%	16.49%	22.52%
EBITDA	161.91M	668.03M	911.77M
EBITDA Margin	5.51%	19.94%	26.12%
Net Income	-146.92M	151.70M	373.78M
Net Income Margin	-5.00%	4.53%	10.71%
R&D	173.08M	216.04M	162.61M
R&D as % of Total Revenue	5.89%	6.45%	4.66%
Interest Expense	166.72M	220.87M	242.51M
Interest Expense % of Total Revenue	5.67%	6.59%	6.95%

Balance Sheet

Currency: CAD	2024-03-31	2025-03-31	2026-03-31
Total Assets	4.04B	4.85B	4.54B
Total Liabilities	3.31B	4.56B	5.10B
Total Equity	732.53M	290.59M	-557.93M
Cash	421.35M	77.97M	56.99M
Total Debt	1.87B	2.65B	3.52B
Net Debt	1.45B	2.57B	3.46B

Cash Flow

Currency: CAD	2024-03-31	2025-03-31	2026-03-31
Operating Cash Flow	570.90M	554.41M	640.96M
Investing Cash Flow	-2.70B	-627.87M	-177.07M
Financing Cash Flow	-281.67M	-279.19M	-483.46M
Capital Expenditure	111.53M	244.09M	181.97M
Free Cash Flow	459.38M	310.33M	458.98M
Dividends Paid	0	163.95M	1.11B
FCF to OCF	80.47%	55.97%	71.61%
Dividend Paid to FCF	0.00%	52.83%	241.76%

Earnings

Report Date	Aug 12, 2026	Nov 11, 2026
EPS Estimate	0.46	0.43
EPS Actual	0.70	-
Surprise	52.17%	-
Timing	Pre-market	Pre-market

Key Statistics & Ratios

Market Cap7.12B

Enterprise Value10.31B

Trailing P/E0.00

Forward P/E16.10

Price / Sales2.23

Price / Book21.54

EPS-0.12

Book Value1.53

Revenue (TTM)3.20B

Gross Profit (TTM)1.62B

EBITDA761.63M

Profit Margin-0.85%

Operating Margin11.44%

Return on Equity0.00%

Return on Assets14.24%

Shares Outstanding228.50M

Shares Float228.18M

Dividend Yield0.19%

Dividend Rate0.06

Payout Ratio8.57%

Dividends

20261×

0.06Sep 15, 2026